Facebook Linkedin RSS Twitter Youtube
Home 2024

CRISPR Therapeutics

Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials
Drug Discovery

Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials

A Story of Perseverance: An Interview with Matthew Porteus
GEN Edge

A Story of Perseverance: An Interview with Matthew Porteus

CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing
Genome Editing

CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing

Top 10 Publicly Owned Gene Editing Therapy Companies
A-Lists

Top 10 Publicly Owned Gene Editing Therapy Companies

CRISPR Concerns Won’t Spoil Its Promise—If We Use the Right Tools
GEN Edge

CRISPR Concerns Won’t Spoil Its Promise—If We Use the Right Tools

StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles
Drug Discovery

StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles

On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough
GEN Edge

On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough

Sickle Cell Salvation: The Victoria Gray Interview
Genome Editing

Sickle Cell Salvation: The Victoria Gray Interview

FDA Approves the First CRISPR Therapy for Sickle Cell Disease
Genome Editing

FDA Approves the First CRISPR Therapy for Sickle Cell Disease

FDA Approves Casgevy, the First CRISPR Therapy, for Sickle Cell Disease
Genome Editing

FDA Approves Casgevy, the First CRISPR Therapy, for Sickle Cell Disease

123Page 1 of 3
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.